BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24129405)

  • 1. Tsc1 deficiency-mediated mTOR hyperactivation in vascular endothelial cells causes angiogenesis defects and embryonic lethality.
    Ma A; Wang L; Gao Y; Chang Z; Peng H; Zeng N; Gui YS; Tian X; Li X; Cai B; Zhang H; Xu KF
    Hum Mol Genet; 2014 Feb; 23(3):693-705. PubMed ID: 24129405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberous sclerosis complex 1-mechanistic target of rapamycin complex 1 signaling determines brown-to-white adipocyte phenotypic switch.
    Xiang X; Lan H; Tang H; Yuan F; Xu Y; Zhao J; Li Y; Zhang W
    Diabetes; 2015 Feb; 64(2):519-28. PubMed ID: 25213336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
    Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
    J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.
    Di Nardo A; Kramvis I; Cho N; Sadowski A; Meikle L; Kwiatkowski DJ; Sahin M
    J Neurosci; 2009 May; 29(18):5926-37. PubMed ID: 19420259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
    Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
    Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurogenin 3-directed cre deletion of Tsc1 gene causes pancreatic acinar carcinoma.
    Ding L; Han L; Li Y; Zhao J; He P; Zhang W
    Neoplasia; 2014 Nov; 16(11):909-17. PubMed ID: 25425965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Missense mutations to the TSC1 gene cause tuberous sclerosis complex.
    Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D
    Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex Neurological Phenotype in Mutant Mice Lacking Tsc2 in Excitatory Neurons of the Developing Forebrain(123).
    Crowell B; Lee GH; Nikolaeva I; Dal Pozzo V; D'Arcangelo G
    eNeuro; 2015; 2(6):. PubMed ID: 26693177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex.
    Wang F; Chen X; Li C; Sun Q; Chen Y; Wang Y; Peng H; Liu Z; Chen R; Liu K; Yan H; Ye BH; Kwiatkowski DJ; Zhang H
    Oncogene; 2014 Aug; 33(34):4352-8. PubMed ID: 24077282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
    Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
    J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of TSC-mTOR signaling on immune cells in immunity and autoimmunity.
    Yang H; Wang X; Zhang Y; Liu H; Liao J; Shao K; Chu Y; Liu G
    J Cell Physiol; 2014 Jan; 229(1):17-26. PubMed ID: 23804073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex.
    Alves MM; Fuhler GM; Queiroz KC; Scholma J; Goorden S; Anink J; Spek CA; Hoogeveen-Westerveld M; Bruno MJ; Nellist M; Elgersma Y; Aronica E; Peppelenbosch MP
    Sci Rep; 2015 Sep; 5():14534. PubMed ID: 26412398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TSC1 controls macrophage polarization to prevent inflammatory disease.
    Zhu L; Yang T; Li L; Sun L; Hou Y; Hu X; Zhang L; Tian H; Zhao Q; Peng J; Zhang H; Wang R; Yang Z; Zhang L; Zhao Y
    Nat Commun; 2014 Sep; 5():4696. PubMed ID: 25175012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.
    Hoogeveen-Westerveld M; Ekong R; Povey S; Mayer K; Lannoy N; Elmslie F; Bebin M; Dies K; Thompson C; Sparagana SP; Davies P; van Eeghen AM; Thiele EA; van den Ouweland A; Halley D; Nellist M
    Hum Mutat; 2013 Jan; 34(1):167-75. PubMed ID: 22903760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma.
    Kong B; Cheng T; Qian C; Wu W; Steiger K; Cao J; Schlitter AM; Regel I; Raulefs S; Friess H; Erkan M; Esposito I; Kleeff J; Michalski CW
    Mol Cancer; 2015 Dec; 14():212. PubMed ID: 26683340
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Ho DWH; Chan LK; Chiu YT; Xu IMJ; Poon RTP; Cheung TT; Tang CN; Tang VWL; Lo ILO; Lam PWY; Yau DTW; Li MX; Wong CM; Ng IOL
    Gut; 2017 Aug; 66(8):1496-1506. PubMed ID: 27974549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
    Rensing N; Han L; Wong M
    Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models.
    Magri L; Cominelli M; Cambiaghi M; Cursi M; Leocani L; Minicucci F; Poliani PL; Galli R
    Dis Model Mech; 2013 Sep; 6(5):1185-97. PubMed ID: 23744272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions.
    Magri L; Cambiaghi M; Cominelli M; Alfaro-Cervello C; Cursi M; Pala M; Bulfone A; Garcìa-Verdugo JM; Leocani L; Minicucci F; Poliani PL; Galli R
    Cell Stem Cell; 2011 Nov; 9(5):447-62. PubMed ID: 22056141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.